UK industry makes third quarter PPRS payment, Department of Health sets 2015 percentage at 10.36%

11 December 2014

The UK pharma industry has made its third quarter payment to underwrite the growth of the medicines bill under the 2014 Pharmaceutical Price Regulation Scheme.

The £79 million ($123 million) payment brings the total payments made by industry so far in 2014 up to £229 million.

The pharma industry agreed to help keep National Health Service expenditure on branded medicines in the scheme flat for two years and within agreed controlled growth levels for another three years in the five-year voluntary PPRS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK